Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sternberg

Showing results (301-310 of 564) with videos related to

Pageof 57
Sort By:
BJU International|November 17, 2007
Novel agents for muscle-invasive and advanced urothelial cancerGuru Sonpavde, Robert Ross, Thomas Powles, et al.
European Urology|April 3, 2012
The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literatureFabio Calabrò, Peter Albers, Carsten Bokemeyer, et al.
Clinical Genitourinary Cancer|February 15, 2020
Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United StatesDaniel J George, Oliver Sartor, Kurt Miller, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 1, 1995
Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis?C N Sternberg, D Raghaven, Y Ohi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trialC N Sternberg, J S de Bono, K N Chi, et al.
Cancer|December 15, 1991
Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumorsA D Seidman, H I Scher, M H Heinemann, et al.
European Urology|October 4, 2020
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer MonitoringFred Saad, Cora N Sternberg, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2010
The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of OncologyRiccardo Valdagni, Peter Albers, Chris Bangma, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2011
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trialD Cella, A S Pickard, M S Duh, et al.
European Urology Oncology|July 6, 2019
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical TrialAndrew J Armstrong, Ping Lin, Celestia S Higano, et al.
Pageof 57

Showing results (301-310 of 564) with videos related to

Sort By:
Pageof 57
BJU International|November 17, 2007
Novel agents for muscle-invasive and advanced urothelial cancerGuru Sonpavde, Robert Ross, Thomas Powles, et al.
European Urology|April 3, 2012
The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literatureFabio Calabrò, Peter Albers, Carsten Bokemeyer, et al.
Clinical Genitourinary Cancer|February 15, 2020
Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United StatesDaniel J George, Oliver Sartor, Kurt Miller, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 1, 1995
Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis?C N Sternberg, D Raghaven, Y Ohi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trialC N Sternberg, J S de Bono, K N Chi, et al.
Cancer|December 15, 1991
Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumorsA D Seidman, H I Scher, M H Heinemann, et al.
European Urology|October 4, 2020
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer MonitoringFred Saad, Cora N Sternberg, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2010
The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of OncologyRiccardo Valdagni, Peter Albers, Chris Bangma, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2011
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trialD Cella, A S Pickard, M S Duh, et al.
European Urology Oncology|July 6, 2019
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical TrialAndrew J Armstrong, Ping Lin, Celestia S Higano, et al.
Pageof 57